Page 64 - வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel monoclonal antibody could pave way for future COVID-19 treatments and vaccines Researchers in the United States have shown that targeting the N-terminal domain (NTD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike protein could achieve broad neutralization of variants of concern. The SARS-CoV-2 virus is the agent responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, and the spike protein is the main structure the virus uses to bind to and infect host cells. This spike is the primary target of neutralizing antibodies following SARS-CoV-2 infection and, therefore, the focus of most vaccine design approaches. The team – from Icahn School of Medicine at Mount Sinai in New York and Washington University School of Medicine in Missouri – says the findings could inform the design of next-generation vaccines that will protect against both currently circulating and newly emerging SARS-CoV-2 variants of concern.

New yorkUnited statesWashington universityGoran bajicSally robertsonIcahn school of medicine at mount sinaiWashington university school of medicineIcahn schoolMount sinaiWashington university schoolபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்வாஷிங்டன் பல்கலைக்கழகம்மிச ou ரிசாலி ராபர்ட்சன்இக்ஹ்ன் பள்ளி ஆஃப் மருந்து இல் ஏற்ற சினை